SCHEMBL1470940

SCHEMBL1470940

C[Si](C)(C)CCCOCCl

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29950014 0.92
SCHEMBL10479233 0.90
SCHEMBL5579 0.83
SCHEMBL9332388 0.83 ALOX15 (0.39) ALOX15
SCHEMBL28558592 0.82
Hydrochloric Acid SCHEMBL1958678 0.81
SCHEMBL28773506 0.78
SCHEMBL29059132 0.76 ALDH1A1 (0.39) ALOX15
SCHEMBL12455815 0.74 ALOX15 (0.35) ALOX15
SCHEMBL6701636 0.74 ALOX15 (0.32) ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111278840-B Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer 癌症研究科技有限公司 2023-11-17 CN disclosed
US-11447505-B1 Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2022-09-20 US disclosed
US-11427578-B1 Substituted pyrrolopyridine-derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-08-30 US disclosed
EP-3668882-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER Cancer Research Technology Limited (GB) 2020-06-24 EP disclosed
CN-111278840-A Pyrrolo [2, 3-B ] pyridine compounds and their use for treating cancer 癌症研究科技有限公司 2020-06-12 CN disclosed
EP-3655406-A1 SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2020-05-27 EP disclosed
WO-2019034890-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-02-21 WO disclosed
WO-2019016071-A1 SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-24 WO disclosed
EP-1799694-B1 METHOD OF PRODUCING SILYLALKOXYMETHYL HALIDE DOW CORNING TORAY CO LTD (JP) 2012-05-09 EP disclosed
US-7915439-B2 Method of producing silylalkoxymethyl halide DOW CORNING TORAY COMPANY, LTD. (JP) 2011-03-29 US disclosed
US-20090203932-A1 Method of Producing Silylalkoxymethyl Halide DOW CORNING TORAY CO., LTD. (JP) 2009-08-13 US disclosed
EP-1799694-A1 METHOD OF PRODUCING SILYLALKOXYMETHYL HALIDE Dow Corning Toray Co., Ltd. (JP) 2007-06-27 EP disclosed
WO-2006040964-A1 METHOD OF PRODUCING SILYLALKOXYMETHYL HALIDE DOW CORNING TORAY CO., LTD. (JP) 2006-04-20 WO disclosed
US-4868189-A ANTICANCER AGENTS SANWA KAGAKU KENKYUSHO CO. (JP) 1989-09-19 US disclosed
EP-0280841-A2 Organo-silicone compounds and use thereof SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1988-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203932-A1 Method of Producing Silylalkoxymethyl Halide CBR3, CBR1, HRH3 ALOX15 4481/4885
US-11447505-B1 Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer PDXK, CCNK, CDC42BPB ALOX15 3317/4885
US-11427578-B1 Substituted pyrrolopyridine-derivatives MAP3K4, MAP4K4, MAP4K3 ALOX15 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.